表皮生长因子受体在皮肤鳞状细胞癌中的作用及其在免疫治疗时代作为治疗靶点的作用。
Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies.
机构信息
The University of Queensland Diamantina Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Faculty of Medicine, University of Queensland, Woolloongabba, Queensland, Australia.
出版信息
Curr Treat Options Oncol. 2020 Feb 3;21(1):9. doi: 10.1007/s11864-019-0697-3.
Recent studies have evidenced the potential of combining anti-EGFR therapies with anti-PD-1/PD-L1 checkpoint therapies. Both anti-EGFR and anti-PD-1/PD-L1 have been separately tested in the treatment of cutaneous SCC (cSCC). Here, we review recent data on EGFR in the context of cancer progression, as a prognostic and as a therapeutic target in cSCC. Anti-EGFR/checkpoint immunotherapy and other combination therapy approaches are discussed. With the advent of immunotherapy, EGFR is still a valid cSCC target.
最近的研究表明，将抗 EGFR 疗法与抗 PD-1/PD-L1 检查点疗法相结合具有潜力。抗 EGFR 和抗 PD-1/PD-L1 已分别在皮肤鳞状细胞癌（cSCC）的治疗中进行了测试。在这里，我们回顾了 EGFR 在癌症进展、预后和 cSCC 治疗靶点方面的最新数据。讨论了抗 EGFR/检查点免疫疗法和其他联合治疗方法。随着免疫疗法的出现，EGFR 仍然是一个有效的 cSCC 靶点。
Zotero 插件